Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study

被引:0
作者
Hiroji Iwata
Norikazu Masuda
Yutaka Yamamoto
Tomomi Fujisawa
Tatsuya Toyama
Masahiro Kashiwaba
Shoichiro Ohtani
Naruto Taira
Takehiko Sakai
Yoshie Hasegawa
Rikiya Nakamura
Hiromitsu Akabane
Yukiko Shibahara
Hironobu Sasano
Takuhiro Yamaguchi
Kentaro Sakamaki
Helen Bailey
Diana B. Cherbavaz
Debbie M. Jakubowski
Naoko Sugiyama
Calvin Chao
Yasuo Ohashi
机构
[1] Aichi Cancer Center Hospital,Graduate School of Medicine
[2] NHO Osaka National Hospital,undefined
[3] Kumamoto University,undefined
[4] Gunma Prefectural Cancer Center,undefined
[5] Nagoya City University Graduate School of Medical Science,undefined
[6] Sagara Hospital,undefined
[7] Hiroshima City Hiroshima Citizens Hospital,undefined
[8] Okayama University Hospital,undefined
[9] Cancer Institute Hospital of Japanese Foundation for Cancer Research,undefined
[10] Hirosaki Municipal Hospital,undefined
[11] Chiba Cancer Center,undefined
[12] Hokkaido P.W.F.A.C. Asahikawa-Kosei General Hospital,undefined
[13] Tohoku University Graduate School of Medicine,undefined
[14] The University of Tokyo,undefined
[15] Genomic Health,undefined
[16] Inc.,undefined
[17] Chuo University,undefined
来源
Breast Cancer Research and Treatment | 2019年 / 173卷
关键词
Breast cancer; Hormonal therapy; Neoadjuvant; Oncotype DX; Recurrence score;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:123 / 133
页数:10
相关论文
共 456 条
[1]  
Fisher B(1997)Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18 J Clin Oncol 15 2483-2493
[2]  
Brown A(1998)A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer Ann Oncol 9 1179-1184
[3]  
Mamounas E(1999)Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS) Ann Oncol 10 47-52
[4]  
Wieand S(2005)Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis J Natl Cancer Inst 97 188-194
[5]  
Robidoux A(2007)Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer Cancer 110 244-254
[6]  
Margolese RG(2008)Locally advanced and inflammatory breast cancer J Clin Oncol 26 786-790
[7]  
Cruz AB(2012)Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes J Clin Oncol 30 1796-1804
[8]  
Fisher ER(2000)Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients Clin Cancer Res 6 616-621
[9]  
Wickerham DL(2013)Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy Breast Cancer Res Treat 139 759-767
[10]  
Wolmark N(2016)Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis JAMA Oncol 2 1477-1486